TUSC2

Across TCGA pan-cancer cohorts, TUSC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TUSC2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TUSC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TUSC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where TUSC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.537	0.270	<.001	91	view →
CCRCC	OS	Tertile	All	0.982	0.486	.004	20	view →
UCEC	DFS	Tertile	All	0.909	1.000	.034	4	view →
LSCC	DFS	Median	II,III,IV	0.854	0.971	.029	3	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	3	view →
GBM	DFS	Quartile	All	0.868	0.640	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TUSC2–PDAC (DFS)

Open the PDAC breakdown →